NCT07441460 2026-03-02A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerShanghai JMT-Bio Inc.Phase 3 Not yet recruiting1,800 enrolled